Fundraising Fox
/Companies
Sign in

Elgia Therapeutics

San Diego, US · Founded 2019 · Delaware corporation · 2 known investors

Find your way into Elgia Therapeutics

Sign up to see every warm intro you have to Elgia Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Elgia Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Elgia Therapeutics is a biopharmaceutical company developing novel molecular therapies for metabolic, inflammatory, and fibrotic diseases. Its work draws on expertise in innate immunity, metabolic syndromes, inflammatory processes, and drug discovery.

BiotechHealthtech

Founders & leadership

Elgia Therapeutics was founded in 2019 by Michael Karin, Michelle Arkin, and Adam Renslo.

MK
Michael Karin
MA
Michelle Arkin
AR
Adam Renslo
BH
Brian HubbardNamed on SEC filing
AS
Alan SaltielNamed on SEC filing
TC
Thomas CollNamed on SEC filing
AF
Ariel FeldsteinNamed on SEC filing

Investors · 2

Also in the syndicate · 2

ChangRong CapitalViva BioInnovatorlead

Reported raises · per SEC filings

Form D private placements

$2.3M disclosed across 1 round · 2020

▶$2.3MraisedMay 2020 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian HubbardDirector
  • Alan SaltielExecutive Officer, Director
  • Thomas CollExecutive Officer
  • Ariel FeldsteinExecutive Officer, Director
Offering amount
$10M
Amount sold
$2.3M
First sale
Apr 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Areteia TherapeuticsAreteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
Coya TherapeuticsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
AltaThera PharmaceuticalsAltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
Lycia TherapeuticsLycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation. Its targeted protein degradation platform, based on research from Carolyn Bertozzi's lab at Stanford, aims to address proteins previously considered undruggable.
Antheia, Inc.Antheia uses a yeast-based biosynthesis and fermentation platform to manufacture Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines, offering an alternative to fragile agricultural sourcing. The company targets pharmaceutical supply chains, aiming to reduce drug shortages and improve reliability for medicines traditionally derived from plants.

Companies working in the same space as Elgia Therapeutics.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2023$180.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Elgia Therapeutics do?
Elgia Therapeutics is a biopharmaceutical company developing novel molecular therapies for metabolic, inflammatory, and fibrotic diseases. Its work draws on expertise in innate immunity, metabolic syndromes, inflammatory processes, and drug discovery.
Who founded Elgia Therapeutics?
Elgia Therapeutics was founded by Michael Karin, Michelle Arkin, Adam Renslo in 2019.
How much funding has Elgia Therapeutics raised?
Elgia Therapeutics has disclosed $2.3M raised across 1 round.
Where is Elgia Therapeutics headquartered?
Elgia Therapeutics is headquartered in San Diego, US.